Last reviewed · How we verify
Intravenous lornoxicam
Lornoxicam is a non-selective nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects.
Lornoxicam is a non-selective nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects. Used for Acute postoperative pain, Acute pain management, Inflammatory conditions.
At a glance
| Generic name | Intravenous lornoxicam |
|---|---|
| Also known as | Lornoxicam: Xefo |
| Sponsor | Diskapi Teaching and Research Hospital |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Lornoxicam blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, the drug decreases inflammatory responses and pain signaling. The intravenous formulation provides rapid onset of action for acute pain and inflammatory conditions.
Approved indications
- Acute postoperative pain
- Acute pain management
- Inflammatory conditions
Common side effects
- Gastrointestinal upset
- Dyspepsia
- Nausea
- Headache
- Dizziness
- Renal impairment
Key clinical trials
- Continuous Lornoxicam Infusion for Orthopaedic Surgery (PHASE1, PHASE2)
- Lornoxicam With Low Dose Ketamine Versus Pethidine to Control Pain of Acute Renal Colic (NA)
- Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy (PHASE2)
- Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. (PHASE2)
- Lornoxicam vs. Paracetamol After Lower Abdominal Surgery (PHASE4)
- Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous lornoxicam CI brief — competitive landscape report
- Intravenous lornoxicam updates RSS · CI watch RSS
- Diskapi Teaching and Research Hospital portfolio CI